

January 8, 2015



## Ceapro Announces Grant of Stock Options

EDMONTON, ALBERTA -- (Marketwired) -- 01/07/15 -- [Ceapro Inc.](#) (TSX VENTURE: CZO) ("Ceapro" or the "Company"), today announced the granting of stock options to its employees, directors, and officers for a total of 950,000 stock options, each with an exercise price of \$0.64. Each grant vests in three equal instalments, the first of which vests immediately with the second and third instalments vesting on the first and second anniversaries of the date of grant. Each option is exercisable, once vested, for a period of ten years from the date of grant.

Of note, a total of 450,000 of the stock options were granted to directors and officers. The granting of all options is subject to TSX Venture approval.

### About Ceapro Inc.

Ceapro Inc. is a Canadian biotechnology company involved in the development of proprietary extraction technology and the application of this technology to the production of extracts and "active ingredients" from oats and other renewable plant resources. Ceapro adds further value to its extracts by supporting their use in cosmeceutical, nutraceutical, and therapeutics products for humans and animals. The Company has a broad range of expertise in natural product chemistry, microbiology, biochemistry, immunology and process engineering. These skills merge in the fields of active ingredients, biopharmaceuticals and drug-delivery solutions. For more information on Ceapro, please visit the Company's website at [www.ceapro.com](http://www.ceapro.com).

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

### Contacts:

Jenene Thomas  
Jenene Thomas Communications, LLC  
Investor Relations and Corporate Communications Advisor  
908-938-1475  
[jenene@jenenethomascommunications.com](mailto:jenene@jenenethomascommunications.com)  
[www.jenenethomascommunications.com](http://www.jenenethomascommunications.com)

Source: Ceapro Inc.